

TCD PHARMA SECURES 6 MILLION EUROS IN VENTURE

CAPITAL FUNDING

The funds will enable the Company to advance the development of TCD-717, its leading product, into Phase I clinical trial for the treatment of cancer.

Madrid, 10 march 2010. - **TCD Pharma**, a biotechnology company that develops innovative personalized and targeted therapies for the treatment of cancer, announces the successful closing of its first financing round, raising more than €6 million. Participants in this capital increase included current shareholders and a select group of new investors. The funds raised by TCD Pharma in this financing round will enable the Company to advance TCD-717, its leading drug, into Phase I clinical studies as well as expend its pipeline of drugs and diagnostic tools.

This round was led by the technology fund SEGURANZA F.C.R., promoted by the regional Economy and Employment ministry of Castilla and León, through its public company ADE Financiación and Real de Vellón SCR. Both funds are managed by Clave Mayor SGCR. Cross Road Biotech, the main shareholder in TCD Pharma, has significantly increased its stake.

Pablo Cabello, president of the company has commented “The new funds will allow the Company to make a great leap forward by entering Phase I clinical development. The investment by new investors such as Clave Mayor as well as follow up investment by current shareholders is a vote of confidence in the scientific basis of the Company and in its potential”.

TCD's Treatment Paradigm - Personalized and Targeted Therapy

TCD's treatment paradigm is both Personalized and Targeted. The approach is based on the identification of particular genes that are either expressed only in tumors or cause cancer cells to behave differently than normal cells ("Targets"). Once identified, the treatment then focuses on the Target resulting in the destruction of tumor cells while leaving normal cells intact.

The patient's eligibility for the treatment is determined by analyzing the patient's tumor for the expression of the specific Target. The diagnosis of the expression of the Target is, therefore, a prerequisite for treatment. Only those patients with high expression levels of the Target in their tumor are eligible for treatment with high confidence of success.

The first Target identified by TCD Pharma is Choline Kinase Alpha.

About Cholin Kinase Alpha

Choline Kinase Alpha (ChoK Alpha) is an enzyme regulating the production of lipids, the building blocks of the cell membrane. ChoK α is a target of unique quality – studies show that 50% of the patients suffering from a broad variety of tumors (lung, breast, colorectal, prostate, bladder, lymphoma and pancreatic cancer) over-express ChoK Alpha. In addition cancer cells react differently to ChoK Alpha inhibition than normal cells - inhibition of ChoK α while merely arresting temporarily the life cycle of normal cells is toxic to cancer cells and results in their destruction.

About TCD-717

TCD-717 is the Company's leading product. This first-in-class, precisely-targeted ChoK Alpha inhibitor is a small molecule that has demonstrated an outstanding therapeutic index. TCD-717 is currently undergoing GLP pre-clinical studies designed to support phase I multi indication clinical study of TCD-717 as a treatment for solid tumors. The clinical study is expected to commence during the second half of 2010. The number of potential patients that would benefit from treatment with TCD-717 is in the millions.

About TCD Pharma

TCD Pharma is a biotechnology corporation that specializes in identifying, developing and commercializing innovative personalized and targeted therapies that address unmet medical needs in the field of oncology. The Company was founded in July 2005 by Cross Road Biotech, a venture capital specializing in early stage investments in biotechnology, and by Prof. Juan Carlos Lacal, Professor of Research in Molecular Biology at the "Alberto Sols" Biomedical Research Institute and is based on technology developed by Prof. Lacal over the past 20 years.

Más información:

Annie Roda

comunicacion@crossroadbiotech.com

Tel. 91 446 78 97